Loading
PARP2 (Poly [ADP-ribose] polymerase 2) is an enzyme. The public catalogues list it as a drug target and a DNA repair gene, and an approved or late-stage drug is recorded against it. Tied to Ovarian cancer, Breast cancer and Prostate cancer.
Poly-ADP-ribosyltransferase that mediates poly-ADP-ribosylation of proteins and plays a key role in DNA repair. Mediates glutamate, aspartate or serine ADP-ribosylation of proteins: the ADP-D-ribosyl group of NAD(+) is transferred to the acceptor carboxyl group of target residues and further ADP-ribosyl groups are transferred to the 2'-position of the terminal adenosine moiety, building up a polymer with an average chain length of 20-30 units. Serine ADP-ribosylation of proteins constitutes the primary form of ADP-ribosylation of proteins in response to DNA damage.
Open Targets scores its association with cancer at 0.63 (direct and indirect evidence; datatypes literature 0.89, animal model 0.32, genetic association 0.00, clinical 0.99).
In plain words · PARP2 (Poly [ADP-ribose] polymerase 2) is an enzyme. The public catalogues list it as a drug target and a DNA repair gene, and an approved or late-stage drug is recorded against it. Tied to Ovarian cancer, Breast cancer and Prostate cancer.
PARP2 (Poly [ADP-ribose] polymerase 2) is an enzyme. The public catalogues list it as a drug target and a DNA repair gene, and an approved or late-stage drug is recorded against it. Tied to Ovarian cancer, Breast cancer and Prostate cancer.
Poly-ADP-ribosyltransferase that mediates poly-ADP-ribosylation of proteins and plays a key role in DNA repair.
No product in this corpus aims at PARP2 yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
Broadly expressed or essential: HPA finds the RNA at low tissue specificity; a medicine acting on the wild-type protein would expose normal tissue too. HPA PARP2: RNA low tissue specificity; high antibody staining in 2 normal tissues; highest cancer staining testis cancer (1 of 12 high). Distribution: 3 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Ovarian cancer, Breast cancer (all types), Prostate cancer); Open Targets associates it with 6 specific cancer types at or above 0.5 (ovarian cancer, breast cancer, fallopian tube cancer, ovarian carcinoma, primary peritoneal carcinoma, prostate cancer). (Rule 7 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas PARP2 tissue; Open Targets ENSG00000129484 associations
First described 1999. Earliest sequence paper UniProt cites for the protein: Ame J.-C. et al, J. Biol. Chem, 1999, "PARP-2, a novel mammalian DNA damage-dependent poly(ADP-ribose) polymerase". Source.
Sources: HGNC HGNC:272 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q9UGN5 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000129484 (association with cancer (MONDO_0004992) 0.63; per-cancer scores at or above 0.5: prostate cancer 0.55, ovarian cancer 0.60, breast cancer 0.57 (GraphQL API, CC0))
Poly-ADP-ribosyltransferase that mediates poly-ADP-ribosylation of proteins and plays a key role in DNA repair. Mediates glutamate, aspartate or serine ADP-ribosylation of proteins: the ADP-D-ribosyl group of NAD(+) is transferred to the acceptor carboxyl group of target residues and further ADP-ribosyl groups are transferred to the 2'-position of the terminal adenosine moiety, building up a polymer with an average chain length of 20-30 units. Serine ADP-ribosylation of proteins constitutes the primary form of ADP-ribosylation of proteins in response to DNA damage. Mediates glutamate and aspartate ADP-ribosylation of target proteins in absence of HPF1. Following interaction with HPF1, catalyses serine ADP-ribosylation of target proteins; HPF1 conferring serine specificity by completing the PARP2 active site. PARP2 initiates the repair of double-strand DNA breaks: recognises and binds DNA breaks within chromatin and recruits HPF1, licensing serine ADP-ribosylation of target proteins, such as histones, thereby promoting decompaction of chromatin and the recruitment of repair factors leading to the reparation of DNA strand breaks. Location: Nucleus; Chromosome (UniProt). Locus 14q11.2 (HGNC).
RNA: low tissue specificity, detected in all normal tissues.
Medium: Adrenal gland, Cerebellum, Cervix, Colon, Epididymis, Esophagus, Hippocampus, Lymph node.
Medium only: breast cancer, carcinoid, cervical cancer, colorectal cancer.
HPA PARP2 tissue · HPA PARP2 pathology · HPA protein class: FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"PARP2" OR ABSTRACT:"PARP2" OR TITLE:"poly ADP-ribose polymerase 2" OR ABSTRACT:"poly ADP-ribose polymerase 2" OR TITLE:"Poly [ADP-ribose] polymerase 2" OR ABSTRACT:"Poly [ADP-ribose] polymerase 2" OR TITLE:"ARTD2" OR ABSTRACT:"ARTD2" OR TITLE:"ADPRTL2" OR ABSTRACT:"ADPRTL2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PARP2, not a curated reading list.